Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate-to-severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Aug 2021 Primary endpoint (Number of Participants With Investigators Global Assessment (IGA) Score of 0 or 1 and Reduction From Baseline of Greater Than or Equal to () 2 Points at Week 16) has been met, according to Results published in the British Journal of Dermatology.
06 Aug 2021 Results published in the British Journal of Dermatology
19 Jun 2020 According to a Sanofi media release, data from this trial will be shared with NMPA in the second half of 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com